United Therapeutics has scored a regulatory green light to start clinical trials for its genetically modified pig kidneys to ...

UBS lowered the firm’s price target on United Therapeutics (UTHR) to $460 from $475 and keeps a Buy rating on the shares. United Therapeutics ...

United Therapeutics (UTHR) announced full enrollment of the TETON 1 study evaluating the use of Tyvaso or treprostinil, inhalation solution or ...

The U.S. Food and Drug Administration has approved the first-ever clinical trials testing pig kidney transplants in people ...

The FDA will allow two biotechnology companies to run clinical trials: United Therapeutics and eGenesis. United Therapeutics ...

United Therapeutics said the FDA has cleared it to begin the first clinical trial testing whether organs from gene-edited ...

Kingswood Wealth Advisors LLC bought a new position in shares of United Therapeutics Co. (NASDAQ:UTHR – Free Report) during ...

Two US biotech companies say the Food and Drug Administration has cleared them to conduct clinical trials of their ...

The US Food and Drug Administration has approved the first-ever clinical trials testing pig kidney transplants in people with kidney failure.

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB), a commercial-stage biopharmaceutical company with a "GOOD" InvestingPro Financial ...

Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), recently executed a series of stock transactions, according to a recent SEC filing. On February 3, Benkowitz sold shares ...

United Therapeutics could eventually use the genetically edited swine to grow organs for human transplant recipients. A ...